e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

23.73 +1.02 (+4.47%)

Streaming Delayed Price Updated: 11:08 AM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2023

From uniQure Inc.

Via GlobeNewswire

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

Analyst Ratings for uniQure ↗

March 07, 2023

Via Benzinga

uniQure to Participate in Multiple Upcoming Industry Conferences in March

March 02, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Stock Trying To Close In On Key Technical Measure ↗

February 28, 2023

uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.

Via Investor's Business Daily

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 28, 2023

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...

Via Benzinga

uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

February 27, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

February 23, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

February 21, 2023

From uniQure Inc.

Via GlobeNewswire

UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline ↗

January 31, 2023

UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

Via Benzinga

uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

January 31, 2023

From uniQure Inc.

Via GlobeNewswire

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Newly Approved Drugs In US Command Over $200,000 On An Average ↗

January 05, 2023

The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2022

From uniQure Inc.

Via GlobeNewswire

uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

December 16, 2022

If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B

From uniQure Inc.

Via GlobeNewswire

uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

November 29, 2022

From uniQure Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

November 25, 2022

On Friday, 68 companies reached new 52-week highs.

Via Benzinga

Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗

November 25, 2022

Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.

Via Benzinga

Why Shares of uniQure Rose 14.61% on Wednesday ↗

November 23, 2022

A big approval for a gene therapy sent the biotech's stock higher.

Via The Motley Fool

The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath ↗

November 23, 2022

And shares of its developer are on a warpath this week.

Via Investor's Business Daily

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗

November 23, 2022

Via Benzinga

uniQure announces FDA approval of first gene therapy for adults with hemophilia B

November 22, 2022

From uniQure Inc.

Via GlobeNewswire

uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022

November 17, 2022

From uniQure Inc.

Via GlobeNewswire

uniQure: Q3 Earnings Insights ↗

November 02, 2022

uniQure (NASDAQ:QURE) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings uniQure beat estimated earnings by...

Via Benzinga

uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 02, 2022

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

October 11, 2022

Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities

From uniQure Inc.

Via GlobeNewswire

uniQure to Participate in Upcoming Industry Conferences in October

October 03, 2022

From uniQure Inc.

Via GlobeNewswire

Roblox's Stock Gets A Price Target Cut By This Analyst; Also Check Out Some Other Major PT Changes ↗

August 09, 2022

Truist Securities boosted the price target on Roblox Corporation (NYSE: RBLX) from $29 to $45. However, Truist Securities analyst Matthew Thornton maintained the stock with a Hold. Roblox shares fell...

Via Benzinga

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday ↗

August 09, 2022

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy